BioSpace News Archive

G3 Pharmaceuticals, a development-stage biopharmaceutical company located in Burlington, MA, today announced the signing of an exclusive Global Development and Option Agreement with Nestlé Health Science, for the development of plant-derived galectin-3 inhibitors for use in nutritional solutions.

The publication highlights the first-ever independent, multicenter study investigating the applicability of the Surfacer System, a novel approach to achieving right-sided, upper body central venous access in patients with obstructions or other conditions that preclude central venous access by conventional methods.

All of the securities in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Collaboration Leverages Scale and Capabilities to Drive Greater Value

• First program from the Topas platform to enter clinical testing • TPM203 is one of several proprietary programs being developed by Topas • Pemphigus vulgaris is an orphan indication that currently has no cure

- First patient in the world treated with new acoustic cluster therapy through a clinical trial - Acoustic cluster therapy combines microbubbles and microdroplets - New therapy could improve targeting of chemotherapy and reduce doses

Technavio has announced its latest market research report titled global breast biopsy devices market 2019-2023.

Avivagen Inc. reported its audited financial results for the year ended October 31, 2019.

Perspective published in Science by Mary K. Crow, MD, discusses new research findings involving a proposed mechanism that could explain the overproduction of type I interferon

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that new data from the vopratelimab ICONIC trial, on the association of a predictive RNA signature with the emergence of ICOS hi CD4 T cells and clinical outcomes